Actigrip Giorno e Notte

Quick links

Choose a section

Quick links to important sections

Advertisements

Actigrip Giorno e Notte

Advertisements
Advertisements
Advertisements

Overview of Actigrip Giorno e Notte

Quick Facts

Property Description
Active Ingredients Acetaminophen, Diphenhydramine, Pseudoephedrine
Form & Type Oral Tablets (Fixed-Dose Combination)
Pharmacological Class Analgesic, Antipyretic, Decongestant, Antihistamine
Common Use Symptomatic relief of cold and flu discomfort
Route of Administration Oral

What Type of Medicine is Actigrip Giorno e Notte?

Actigrip Giorno e Notte is classified as a synthetic fixed-dose combination (FDC) medicinal product, strategically designed as oral tablets with distinct formulations for Day (Giorno) and Night (Notte) use. The preparation contains two separate tablet forms—a white tablet for daytime and an azure-coated tablet for night—reflecting a differential composition to manage symptoms across the full 24-hour cycle. Its availability as a non-prescription product in the Italian market makes it a readily accessible option for adult patients seeking symptomatic relief from acute cold and flu episodes, a use common for FDC preparations of this type.

Composition and Pharmacological Group

The efficacy of the product relies on the synergy of three core active ingredients: Acetaminophen, Pseudoephedrine hydrochloride, and Diphenhydramine hydrochloride. This places the medicine across the pharmacological categories of an analgesic and antipyretic (Acetaminophen), a sympathomimetic decongestant (Pseudoephedrine), and a first-generation antihistamine (Diphenhydramine). The combination of these classes of drugs is established through pharmacological application for managing the multifaceted symptoms of the common cold beyond single-ingredient therapies. The composition is deliberately partitioned, with the sedating Diphenhydramine reserved exclusively for the night tablet, a practice intended for the management of symptoms that disrupt sleep.

General Purpose of the Symptomatic Combination

The general purpose of Actigrip Giorno e Notte is to provide comprehensive, sustained symptomatic relief from the overall discomfort caused by the common cold and flu. A typical scenario for its use involves a patient experiencing headache, mild fever, and nasal congestion. By combining its active components, the product simultaneously targets the most disruptive physical manifestations: reducing pain and fever via the analgesic, clearing nasal congestion with the decongestant, and managing the secretory symptoms of a runny nose with the antihistamine. This integrated approach ensures the patient receives broad relief that sustains across both active hours and periods of rest.

Advertisements

What side effects are possible with Actigrip Giorno e Notte?

Possible Side Effects and Safety Information

The safety profile for Actigrip Giorno e Notte, a combination product, is derived from the known regulatory documentation for its components: Acetaminophen, Pseudoephedrine, and Diphenhydramine.

Officially Documented Adverse Reactions

The adverse reactions listed in regulatory safety documents are grouped by the affected system-organ class. Common reactions are frequently reported, while serious adverse reactions are typically classified as rare or very rare.

Classification System-Organ Classes & Common Effects
Common Nervous System/Psychiatric Disorders: Drowsiness (Night Tablet), Dizziness, Insomnia, Nervousness, Headache. Gastrointestinal Disorders: Dry mouth, Constipation.
Uncommon/Rare Cardiac Disorders: Palpitations, Tachycardia. Renal/Urinary: Urinary retention. Skin/Immune System: Hypersensitivity reactions, rash, blood disorders (e.g., thrombocytopenia).

Serious Adverse Reactions (Regulatory Listings)

Regulatory documentation mandates explicit warnings regarding certain serious risks, most notably: Severe Liver Damage or Failure associated with the Acetaminophen component, especially if the maximum daily limit is exceeded. Other serious documented risks include the potential for Hypertensive Crisis due to Pseudoephedrine and very rare Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Population-Specific Safety Considerations

Official labels address specific patient groups, noting that older adults may experience increased susceptibility to neurological effects like dizziness, confusion, and sedation, and that patients with severe hepatic impairment have a heightened risk of liver toxicity from Acetaminophen. Additionally, safety documents define a time-related pattern where marked drowsiness is most prominent during the initial exposure to the Night Tablet.

Safety-Related Restrictions and Limitations

The use of this medication is subject to high-level restrictions documented in regulatory text. It is contraindicated in individuals with conditions such as severe hypertension, severe coronary artery disease, and narrow-angle glaucoma. Furthermore, the combination is prohibited from co-administration with Monoamine Oxidase Inhibitors (MAOIs) or with other Acetaminophen-containing products to mitigate the risk of severe adverse events.

This structured profile ensures the official risks, from common expected effects to rare serious systemic events, are categorized and linked to their regulatory source, defining the high-level safety boundaries of the medication.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The information below is strictly based on official regulatory documents describing the consequences and required actions in the event of an overdose with a combination product containing Acetaminophen, Pseudoephedrine, and Diphenhydramine.


Element Regulatory Statement
Documented Overdose Presentations Early symptoms include pallor, nausea, vomiting, and abdominal pain (Acetaminophen toxicity). CNS effects include somnolence, hyperpyrexia, excitement, tremors, and seizures (Diphenhydramine/Pseudoephedrine toxicity).
Severe Outcomes Listed Overdose can lead to hepatic cytolysis evolving toward massive and irreversible necrosis (liver failure). Severe poisoning may result in coma, cardiovascular collapse, or cerebral hemorrhage (stroke) [Source: SmPC].
Population-Specific Notes In children, overdose may cause heightened CNS symptoms, including excitement, insomnia, nervousness, and epileptic seizures. The risk of liver damage may be higher in adults with chronic alcohol use.
Emergency Action Required Seek immediate medical attention for any suspected overdose, even if no symptoms are apparent. If symptoms include seizures, trouble breathing, or unconsciousness, contact emergency services immediately.

Official Management Structure

Treatment for overdose is symptomatic and supportive. Regulatory documents specify the need for rapid measures such as gastric lavage or activated charcoal administration in acute poisoning. The specific antidote for the Acetaminophen component, N-acetylcysteine (NAC), is required for treatment, especially when exposure exceeds defined regulatory thresholds.

Advertisements

Therapeutic Uses of Actigrip Giorno e Notte

What Actigrip Giorno e Notte Treats: Main Uses and Benefits

The primary use of Actigrip Giorno e Notte is to provide supportive relief for the disruptive symptom clusters associated with the common cold and general influenza. This medication is commonly used across conditions presenting with acute episodes when a patient experiences concurrent manifestations, including: symptoms related to physical discomfort like headache and generalized body aches, mild fever, and symptoms of nasal distress such as congestion and a runny nose. The goal is to ease the symptomatic burden, as the combination of active ingredients is considered relevant for managing these acute manifestations.

The medication is applied in clinical settings that involve acute or unstable symptom patterns requiring short-term symptomatic assistance tailored to the patient’s activity cycle. This includes using the specialized night tablet to address symptoms that interfere with achieving rest, thereby supporting the patient during difficult episodes.


“The Day/Night formulation supports the patient during acute symptomatic phases by providing tailored relief that addresses both daytime activity and nighttime rest.”


Quick Fact: Symptom Support Overview
Systemic Discomfort May assist with managing mild pain and fever.
Nasal Function Is used for managing congestion and supports easier breathing.
Secretions May assist with managing runny nose and frequent sneezing.
Rest/Sleep Helps with symptoms that disrupt nighttime rest.
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Classification Eligible Population Prohibited Population
Age-Based Adults and adolescents aged 12 years and older Children under 12 years of age
Physiological State N/A Pregnant or breastfeeding patients

Condition-Specific Eligibility Rules

Official regulatory documents classify use as Contraindicated for patients with the following existing conditions:

  • Severe Hypertension, Cardiovascular Disease, or history of Stroke.
  • Glaucoma, Diabetes Mellitus, or Hyperthyroidism.
  • Severe Liver Disease or severe Renal Impairment.
  • History of Epilepsy or G6PD deficiency.
  • Prostatic Hypertrophy or stenosis causing difficulty urinating.

Pharmacological and Conditional Restrictions

  • Absolute Exclusion: The medicine is Contraindicated if currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last 14 days.
  • Drug Duplication: Use is Contraindicated if currently taking any other medication that contains Paracetamol or Diphenhydramine.
  • Conditional Use: Caution and supervision are required for the Geriatric population, patients with moderate hepatic or renal impairment, or those with pre-existing conditions like asthma or chronic respiratory disease.

Regulatory Conclusion

Eligibility is strictly defined by regulatory documents through exclusions covering age, specific severe comorbidities, and organ status. The product is fundamentally conditional on the patient being an adult or adolescent over 12 and the documented absence of all listed prohibitive clinical and pharmacological states.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Actigrip Giorno e Notte defines critical interaction constraints across several medicinal categories. The most severe restriction is the formal contraindication against co-administration with Monoamine Oxidase Inhibitors (MAOIs). Use is strictly prohibited during and for a mandatory 14-day period following the cessation of MAOI therapy.

Further prohibitions apply to the co-administration of other products containing Acetaminophen or Diphenhydramine to prevent dosage excess and mitigate the documented risk of hepatotoxicity. Due to the decongestant component, co-administration with other Sympathomimetic Agents carries the risk of severe pharmacodynamic consequences, including hypertensive crisis and tachycardia.

The label also documents significant interactions with substances affecting the central nervous system. Co-administration with CNS Depressants (including alcohol, sedatives, and tranquilizers) is restricted because of the additive effect that reinforces sedation. Furthermore, the effect of certain Antihypertensive agents (e.g., alpha- and beta-blockers) may be partially nullified by the sympathomimetic component.

For the Acetaminophen component, prolonged use with Coumarin Anticoagulants (like Warfarin) is noted to increase the risk of bleeding. Special caution is also officially noted for patients with chronic alcohol consumption, as this population has a heightened susceptibility to Acetaminophen-induced liver damage. Treatment must be discontinued prior to scheduled surgery.

Advertisements

Mechanism of Action

Actigrip Giorno e Notte provides its effect through a dual-action pharmacodynamic mechanism. The decongestant component in the daytime tablet acts as an alpha1-adrenergic receptor agonist, selectively targeting and binding to receptors on the vascular smooth muscle of arterioles in the nasal mucosa. This binding initiates a cascade leading to vasoconstriction, which results in decreased tissue edema and reduced localized blood flow. The analgesic component functions centrally by inhibiting cyclooxygenase (COX) activity, primarily COX-2, in the central nervous system. This enzymatic inhibition leads to a reduction in the synthesis and release of prostaglandins, thereby contributing to the attenuation of the pyretic response. The nighttime tablet utilizes an antihistamine, which acts as a competitive antagonist of H1 histamine receptors, specifically those located in the brain. The resulting H1 receptor blockade modulates neurotransmission and cellular signaling, inducing system-level physiological consequences that include central nervous system depression and sedation.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Actigrip Giorno e Notte — Official Administration Guidelines

The following guidelines reflect the official administration instructions for Actigrip Giorno e Notte as defined in the product information.


Administration Scope

Feature Guideline
Route of administration Oral use, swallowing the tablets whole without chewing, typically with water.
Dosing schedule Day (Giorno) Tablet: One white tablet administered three times per day (morning, midday, and afternoon). Night (Notte) Tablet: One azure-coated tablet administered once per day, taken in the evening before retiring to bed.
Timing in relation to meals (if applicable) Official instructions do not specify a requirement to be taken with or without food.
Preparation requirements (if applicable) The tablets must be swallowed whole; no preparation or modification is specified.
Age-group administration rules The product is approved for use in adults and children over 12 years of age. Use is not recommended for pediatric patients under 12 years of age.
Missed-dose rules If a scheduled dose is missed, a double dose must not be taken to compensate for the forgotten administration.
Special procedural conditions A minimum time interval of 4 to 6 hours must be maintained between successive administrations of the Day tablet.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral solid dosage (fixed-dose combination tablets).
Frequency pattern Structured daily regimen requiring divided use (three doses during the day, one dose at night).
Regulatory basis Based on approved product labeling and standardization for the combination.
Use-context constraints The maximum allowed duration of continuous treatment is 3 consecutive days.

Resulting Procedural Structure

Official step sequence:

  • Administer one white (Day) tablet three separate times throughout the day (morning, midday, afternoon).
  • Maintain a minimum interval of 4 to 6 hours between each daytime dose.
  • Administer one azure-coated (Night) tablet once per day, specifically in the evening before retiring to bed.
  • Limit the entire course of use to a maximum of 3 consecutive days, discontinuing treatment if the intended result is not achieved within this period.

Connection to the overall use protocol: The official protocol establishes a precise four-dose, 24-hour cycle using two different tablet compositions, defining the exact route (oral) and frequency of administration. This structured regimen specifies the maximum daily intake and sets a strict 3-day limit on the total course duration, thereby standardizing the short-term administration of the combination product. The documented rules explicitly govern the proper handling of the product regarding age restrictions and administration timing.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Actigrip Giorno e Notte

This section provides a summary of the clinical research base relevant to the active components of Actigrip Giorno e Notte, detailing the type of evidence available without providing clinical advice or treatment recommendations. The findings describe group patterns observed in studies and are not predictions of individual patient outcomes.


Evidence for Acute Daytime Symptom Relief

Research has explored the combination of the analgesic (Acetaminophen) and the decongestant (Pseudoephedrine) in short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were conducted in research contexts involving fluctuating symptoms of the common cold in adult populations. Research explored how outcomes related to physical discomfort (like pain and fever) and outcomes related to nasal congestion changed over time.

Studies explored these changes using both patient-reported outcomes describing perceived discomfort and objective measures of congestion, such as Nasal Airflow Conductance (NAC). Findings describe patterns observed in the studies where research highlights changes measured during the short-term, acute phase of symptoms. Results apply only to the populations studied in the core research.


Evidence for Symptoms Affecting Nighttime Rest

Research has explored the night formula's combination—the analgesic (Acetaminophen) and the sedating antihistamine (Diphenhydramine). This combination was studied for evaluating symptoms that may interfere with sleep, outcomes capturing phases of heightened symptom activity. The research base includes Controlled Clinical Trials (CCTs) and pharmacokinetic (PK) studies which was evaluated in adult populations.

Studies examined the combination's influence on patient-reported outcomes describing perceived discomfort related to sleep disruption, and the evaluation of outcomes linked to inflammatory or irritative states. Studies report patterns of how symptoms evolved in the observed populations, and the inclusion of the sedating component may be linked to changes measured in subjective sleep quality during the trial period.


What Is Still Uncertain about the Combination's Research Base

A synthesis of the evidence highlights key gaps. The evidence quality varies across studies, and the focus has historically been on the acute phase of illness. There is limited information for long-term outcomes or the durability of effect for this specific fixed dose regimen. Evidence is limited for the use of the combination components in groups such as children, pregnant populations, or older adult patients. Certainty remains low in areas where comparative evidence is lacking or where data for certain groups remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Actigrip Giorno e Notte (FAQ)


Q: Why does the Night tablet seem to make me sleepy?

A: The Night tablet contains the active ingredient diphenhydramine, which is classified in official sources as a sedating antihistamine. This component acts on the central nervous system, and the expected effect documented in official safety information is drowsiness. This is why the Night tablet is reserved for use before bedtime.


Q: How long does the effect of one Night tablet typically last?

A: The dosing schedule for the Night tablet is once daily, administered in the evening before retiring to bed. The duration of effect is intended to support the required period of rest, based on the dosing schedule of one administration before bedtime.


Q: What happens if I accidentally take a Night tablet during the day?

A: Official product information explicitly warns that the Night tablet can cause drowsiness or sedation. Due to the documented potential for drowsiness, the use of the Night tablet during waking hours may affect the ability to perform tasks that require alertness, such as driving or operating machinery.


Q: If I only have a stuffy nose during the day, can I just take the Day tablets?

A: The product is indicated for the treatment of cold and flu symptoms using a specific Day and Night regimen. The Day tablet contains the components (paracetamol and pseudoephedrine) that address daytime symptoms like nasal congestion. It is important that any use of the Day tablet, even alone, respects the maximum daily dose and frequency guidelines described in the official regulatory documents.


Q: Is it possible to become dependent on this medicine if used for too long?

A: Official regulatory documents explicitly establish a maximum limit of 3 consecutive days for the continuous use of this product. This strict time limit is established as a precaution to prevent health risks documented to be associated with use beyond the recommended duration.


Q: Can I use Actigrip Giorno e Notte for a sore throat or just a stuffy nose?

A: The product is officially indicated for the symptomatic relief of cold and flu discomfort, including headache, fever, and nasal congestion. The paracetamol component provides a pain-relieving action that may include discomforts associated with pain and fever.


Q: Does using the Night tablet affect the quality of sleep?

A: The Night tablet contains the sedating antihistamine diphenhydramine. The inclusion of the sedating antihistamine is aimed at addressing symptoms that might interfere with rest.


Q: What should I do if I experience dizziness after taking the Day tablet?

A: Dizziness is listed in official safety documentation as a common side effect of the medicine. Official regulatory guidance indicates that if new symptoms or side effects occur, or if they worsen or persist, the discontinuation of treatment should be discussed.


Q: Is it normal to feel dry mouth while using the Night tablet?

A: Yes, dry mouth is listed in official safety documentation as a common adverse reaction associated with the use of this product. This effect is specifically linked to the presence of the antihistamine component, diphenhydramine, in the Night tablet.


Q: How does the Day tablet help with nasal congestion?

A: The Day tablet contains the decongestant pseudoephedrine. This ingredient works to reduce the swelling of blood vessels in the nasal passages, which helps facilitate breathing by improving airflow through the nose.


Q: Can this medicine cause problems with driving or operating machinery?

A: Official product information explicitly warns that the Night tablets can cause drowsiness or sedation. For this reason, patients are advised not to drive a motor vehicle or operate machinery until they are certain they do not suffer from this effect.


Q: Is Actigrip Giorno e Notte gluten-free or suitable for people with Celiac disease?

A: Official regulatory documents include a full list of inactive ingredients, or excipients, for the tablets. This information is provided to allow individuals to verify the composition against specific needs or intolerances.


Q: Does the product contain any ingredients that could show up on a standard drug test?

A: Official regulatory documents include an explicit warning stating that the product contains substances prohibited for doping. This warning relates to the presence of the ingredient pseudoephedrine in the Day tablet.


Q: Are there different strengths or formulations of Actigrip Giorno e Notte available?

A: The product is classified as a specific fixed-dose combination (FDC). The official documentation describes this specific FDC composed of the two distinct tablet types for Day and Night use.


Q: Why is the use of other sympathomimetics contraindicated with this product?

A: The contraindication is established due to the documented risk of severe health consequences when combined with other sympathomimetic agents. This type of interaction carries a documented risk of a severe increase in blood pressure.


Q: What is the meaning of the term 'non-sedating' when referring to the Day tablets?

A: The Day tablet is designed to treat symptoms during active waking hours. It is described as 'non-sedating' because, unlike the Night tablet, it excludes the specific first-generation antihistamine component that is documented to cause drowsiness.


Q: What research is available on the use of Actigrip Giorno e Notte in adolescents?

A: The product is officially approved for use in adults and adolescents over 12 years of age. Research themes explored focus generally on adult populations, but the eligibility criteria allows use for the 12+ age group.


Q: Do the official patient leaflets mention specific environmental factors that might affect the medicine?

A: Official documentation specifies several conditions for storage. The product must be stored at a temperature not exceeding 25 C and kept in its original packaging to ensure protection from light and humidity, as required to maintain its stability.


Q: Are there specific warnings for athletes using this medication?

A: Yes, official regulatory documents include an explicit warning stating that the product contains substances prohibited for doping, which is relevant information for athletes.


Q: What is the difference between Actigrip Giorno e Notte and a single-ingredient cold product?

A: This product is classified as a fixed-dose combination (FDC) that contains three active ingredients: an analgesic, a decongestant, and an antihistamine (in the night dose). This composition is designed to offer symptomatic relief for multiple cold symptoms simultaneously.


Q: Can I take the Day tablet if I also have a mild headache?

A: The Day tablet contains paracetamol, which is classified as an analgesic and antipyretic. The product is officially indicated for the symptomatic relief of cold and flu symptoms, which includes headache.


Q: Is it possible to take only the Night tablet if my symptoms are worse at bedtime?

A: The Night tablet is administered once per day in the evening. Any use of the Night tablet alone should follow the official guidance regarding maximum daily intake and the overall total duration of use, which is limited to 3 consecutive days.


Q: Are there known laboratory test interference issues with this medication?

A: Regulatory information documents that the paracetamol component may interfere with the determination of uric acid and blood glucose levels when certain specific laboratory test methods (phosphotungstic acid and glucose oxidase-peroxidase methods) are used.


Q: What research evidence themes are generally available regarding the combination of ingredients in this drug?

A: Research themes explored for this fixed-dose combination focus on the evaluation of outcomes related to physical discomfort, such as pain and fever, and outcomes related to nasal congestion. These studies are typically conducted during the short-term, acute phase of common cold symptoms in adult populations.


Q: What is the recommended approach if a person forgets to take the Day tablet?

A: Official instructions state that a double dose must not be taken to compensate for a forgotten administration. Official instructions highlight the importance of maintaining a minimum time interval of 4 to 6 hours between successive administrations of the Day tablet.


Q: Can the ingredients in Actigrip Giorno e Notte cause insomnia for some people?

A: Insomnia is listed in official safety documentation as a common adverse reaction. This adverse reaction is often associated with the decongestant component (pseudoephedrine) found in the Day tablet.

Advertisements

How should Actigrip Giorno e Notte be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing Actigrip Giorno e Notte to maintain its stability. The product must be stored at a temperature not exceeding 25 C and must be kept in its original packaging to ensure protection from both light and humidity. The expiration date is only valid if the product is kept intact and stored correctly under these required environmental constraints.

Child-Safety and Disposal

The medicine must be stored out of the sight and reach of children.

Regarding disposal, regulatory instructions explicitly state that the product must not be thrown away into wastewater or with household waste. Unused or expired medication must be handled as pharmaceutical waste; patients are directed to ask a pharmacist how to properly eliminate the product, which is a required step for environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actigrip Giorno e Notte found in:

A-Z Index: